UNSPSC 51182600: Combination hormones/synthetics/modifiers

This classification denotes combination drugs and preparations that consist in whole or part of chemical substances which originate in human glands, or are synthesized from secretions therefrom, having a specific regulatory effect on the activity of a certain organ or organs, and which bear the name HORMONES, or otherwise, additional preparations that amplify. inhibit, or alter affects of the same.

Typical combination hormone/synthetic/modifier constituents are cholecalciferol, fluoxymesterone, hydroxyprogesterone, medroxyprogesterone, methyltestosterone, norethindrone, norgestimate, progesterone, risedronate, and testosterone.

UNSPSC 51182600 Combination hormones/synthetics/modifiers is a Class code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products for distribution through authorized wholesalers to participating state and local healthcare facilities. The scope of work covers manufacturers and suppliers providing comprehensive product portfolios with specific National Drug Codes, SKUs, and pricing in multiple formats (flat price, net price, WAC-minus structures), along with compliance documentation under current Good Manufacturing Practices and the Drug Supply Chain Security Act. Vendors must maintain relationships with authorized wholesalers and demonstrate electronic data interchange capability. Issuing bodies under this code include cooperative purchasing alliances administered by state procurement offices; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), for example, administers contracts across multiple participating states and local government facilities.

Recent activity centers on the Upper Midwest and Pacific Northwest, with MMCAP's January 2026 RFP explicitly extending to Oregon. The Minnesota Department of Administration's Office of State Procurement issued MMCAP's Request for Proposal S1070000015802 on January 20, 2026, with a response deadline of March 26, 2026, seeking multiple contract awards for generic pharmaceuticals and OTC products to take effect July 1, 2026. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remainder on compliance with administrative format requirements, EDI capability, and administrative-fee agreement. Vendors must carry commercial general liability of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, with performance penalties ranging from $200 to $1,500 per violation. The contract structure allows sole, dual, or multi-awards at MMCAP's discretion with a two-year initial term and optional extensions.